Antibody biotech Diagonal Therapeutics lands $128M to pursue rare diseases
2024-04-03
抗体药物偶联物
Diagonal Therapeutics has launched with $128 million to go after an orphan disease that leads to chronic anemia, and another antibody for the same rare disease that is also targeted by Merck’s
newly approved drug
, Winrevair. Just last week, the biotech was congratulating its chief scientific officer on his contributions to the same Merck drug.
The Cambridge, MA-based biotech came out of stealth on Wednesday morning with the seed and Series A funds from blue-chip backers like BVF Partners and Atlas Venture. Additional investors include Lightspeed Venture Partners, RA Capital Management, Frazier Life Sciences, Viking Global Investors
,
Velosity Capital and Checkpoint Capital.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
适应症
靶点
-热门报告
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。